MGTX meiragtx.com: Enterprise Value-to-Revenue Ratio

meiragtx.com (MGTX) - corporate logo

The EV/Sales ratio reflects market expectations for MeiraGTx Holdings plc (MGTX), where 1814.46 serves as the base parameter value. MeiraGTx Holdings plc (MGTX) treats rare vision and CNS pathologies, generating revenue through partnerships and the correction of genetic defects. The business relies on a closed-loop production cycle of riboswitch vectors. High demand inelasticity and patent protection ensure the asset remains independent of global economic fluctuations.

MGTX: MeiraGTx Holdings plc EV/Sales Multiple 11/23/2025 - 11/21/2026

MeiraGTx Holdings - analytical breakdowns and key metrics (MGTX)

- price and consensus price forecast:
- company stock capitalization data:
Initial company analysis:MGTX (MeiraGTx)
Finished products of MeiraGTx

MeiraGTx Holdings plc (MGTX) is spending significant reserves on clinical trials amid a shortage of current revenue. This indicator compares the total enterprise value, including debt, with sales volume, excluding the impact of the credit load. This allows for an objective assessment of the market value of assets relative to operational efficiency. The analysis helps detect revenue stagnation or artificial price stabilization in a timely manner. Monitor the enterprise value-to-revenue dynamics to identify risks of a sudden drop in quotes.

Direct competitors

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|Regenxbio (RGNX) - Enterprise Value-to-Revenue Ratio|SLDB - Total Company Value-to-Revenue Ratio|OCGN (Ocugen Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio PACB|Enterprise Value-to-Revenue Ratio Benitec (BNTC)|Design Therapeutics Inc - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Rocket Pharma RCKT|EV/Sales Multiple 4DMT FDMT|LXEO - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Korro Bio Inc.|EDIT: EV/Sales Multiple|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple